Home
Mylan N.V.

Mylan N.V. Market Share Analysis for November 2025

Health > Biotechnology and Pharmaceuticals

Domainmylan.com

Year Founded1961

Employees> 10001

Annual Revenue> $1B

Mylan N.V.

Mylan N.V. (including company regionals)

mylan.com

See more website traffic and engagement information

Mylan N.V. Revenue up to November 2025 is > 1B

revenue generated by Mylan N.V. top domains

Mylan N.V. top domains revenue over 3 years

Revenue for Mylan N.V. top domains

mylan.com> 1B

See more with Sales Intelligence

Total visits to Mylan N.V.'s top domains

Understand Mylan N.V. market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

mylan.com23.2K

See more with Sales Intelligence

Avg. visit duration in Mylan N.V.'s top domains

Analyze Mylan N.V. engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

mylan.com00:00:34

See more with Sales Intelligence

Avg. pageviews on Mylan N.V.'s top domains

See how Mylan N.V. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

mylan.com1.59

See more with Sales Intelligence

Mylan N.V. top competitors by domain

Top similar sites in November 2025, ranked by their affinity

pfizer.comCompany NamePfizerEmployees> 10001HQUnited States, New York, New York CityAnnual revenue> $1BTotal visits2.7MHealth > Biotechnology and Pharmaceuticals

Top technologies used by Mylan N.V.

These are the website technologies, by industry, used by Mylan N.V. top domains

Social (6)

Google+ Platform

Marketing (3)

Google Marketing Platform

Mobile (3)

Meta Viewport

Advertising (2)

DoubleClick

More Technologies

10

See all

News & Signals from Mylan N.V.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMylan launches generic version of blockbuster eye drug Eylea.Regeneron (NASDAQ:REGN) won a temporary restraining order that blocks drugmakers including, Mylan Pharmaceuticals/Biocon Biologics, from launching a generic version of its blockbuster eye drug Eylea.

NewsMylan files suit against P&G.Mylan Laboratories has filed a lawsuit against Procter & Gamble and Watson Pharmaceuticals, alleging that Watson's "authorized generic" deal for Procter & Gamble's Macrobid antibiotic (nitrofurantoin) during Mylan's 180-day exclusivity period...

NewsMylan has issues with illegal diversion of Alprazolam tablets.Telangana: notice to Mylan Labs for illegal diversion of Alprazolam tablets.